T-MSC granted the patent authorization of Japan and Australia

2018-01-10 11:09:26

T-MSC granted the patent authorization of Japan and Australia

The core technology of ImStem Biotechnology Inc. has recently been granted the patent authorization of the national patent office of Japan and Australia. As the currently best embryo derived mesenchymal stem cell production method, T-MSC (Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof) has acquired the patented invention of the US National Patent Office (Patent No. 9745551), the China National Intellectual Property Office (ZL 2013 8 0036985.7), the European Patent Office (13816490.0-1402), respectively, in August 2017.

On December 19, 2017, T-MSC was granted the patent authorization (Patent No. 特愿2015-521809) of the Japanese Patent Office. On December 20, 2017, the patent application of T-MSC (Application No. 2013290146) was accepted and will be officially advertised on January 18, 2018 through the Australian Intellectual Property Office.

T-MSC is characterized by high cell activity, high differentiation potential, no-donor dependence, infinite amplification and stable efficiency, which makes it possible to standardize mass production of stem cell products and can be widely used in the future treatment of the human autoimmune system disease. Of which long-term experiments on animals and all pre-clinical tests have been completed, the T-MSC treatment of multiple sclerosis was reviewed on the US FDA Pre - IND meeting in March 2016. The lab will proceed clinical I period prior to June 2018. ImStem is commited to the stem cell medical revolutionary and the contribution to the benefit of human health!


MetInfo enterprise content manager system | MetInfo CMS

MetInfo enterprise content manager system | MetInfo CMS

MetInfo enterprise content manager system | MetInfo CMS



Hengqin pins its future on attracting talent
2017/12/21

Hengqin pins its future on attracting talent

Hengqin pins its future on attracting ta..

9/12/2017-ImStem, UConn Obtain U.S. Patent for Mesenchymal Stem Cell Technology to Treat MS, Other Diseases
2017/12/11

9/12/2017-ImStem, UConn Obtain U.S. Patent for Mesenchymal Stem Cell Technology to Treat MS, Other Diseases

The U.S. Patent and Trademark Office has issued a patent for human embryonic ste..

6/05/2014-ImStem Biotechnology, Inc. Makes Progress on Multiple Sclerosis Treatment with Embryonic Stem Cells
2017/12/11

6/05/2014-ImStem Biotechnology, Inc. Makes Progress on Multiple Sclerosis Treatment with Embryonic Stem Cells

Farmington, Conn. - June 5, 2014. ImStem Biotechnology, Inc.(ImStem) announced t..

6/10/2013 -ImStem won 1.1 million stem cell research grant from State of Connecticut
2017/12/11

6/10/2013 -ImStem won 1.1 million stem cell research grant from State of Connecticut

IImStem won 1.1 million stem cell research grant from State of ConnecticutNine s..

2/18/2013 - New Stem Cell Company Opens Lab at UConn Health Center
2017/12/11

2/18/2013 - New Stem Cell Company Opens Lab at UConn Health Center

A new stem cell company, ImStem Biotechnology Inc., is the latest research ventu..